Brad Hively compensation by year
Starling Oncology Summary Compensation Table · all 4 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Salary | $400,000 | $430,768 | $579,208 | $293,500 |
| Bonus | $11,228 | $49,987 | $0 | $0 |
| Stock awards | $0 | $2,614,116 | $962,533 | $167,638 |
| Option awards | $0 | $8,396,264 | $4,885,594 | $202,636 |
| Non-equity incentive | $188,772 | $132,800 | $190,188 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $11,400 | $11,600 | $12,200 | $551,416 |
| Total | $611,400 | $11,635,536 | $6,629,723 | $1,215,190 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Starling Oncology, Inc. DEF 14A filed May 2, 2024, accession 0001193125-24-129457, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Starling Oncology, Inc. filed document, accession 0001193125-24-129457. Every figure is read from that document and cited to the page and table it appears in. Filed May 2, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 212,070 | $432,623 | — |
| RSU | 168,512 | $343,764 | — |
| RSU | 141,380 | $288,415 | — |
| RSU | 77,602 | $158,308 | — |
| RSU | 54,235 | $110,639 | — |
| RSU | 42,652 | $87,010 | — |
| Option | 251,771 | — | $0.85 |
| Option | 275,282 | — | $7.09 |
| Option | 393,891 | — | $1.87 |
| Option | 421,280 | — | $0.48 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Starling Oncology, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
26 Form 4 lines since the FY2023 proxy (filed May 2, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-08-21 | Sale | 10b5-1 | 298,853 | $6.51 | 411,976 |
| 2026-07-27 | Grant or award | — | 27,108 | $0.00 | 710,829 |
| 2025-12-15 | Sale | — | 13,333 | $3.77 | 683,721 |
| 2025-11-20 | Grant or award | — | 32,407 | $0.00 | 697,054 |
| 2025-11-20 | Grant or award | — | 41,667 | $0.00 | 664,647 |
| 2025-08-19 | Sale | — | 20,221 | $4.06 | 622,980 |
| 2025-06-03 | Exercise or conversion | — | 684,528 | $0.85 | 1,396,561 |
| 2025-06-03 | Exercise or conversion | — | 105,320 | $0.48 | 1,501,881 |
The 8 most recent of 26 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Starling Oncology’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Brad Hively · this page | Previous Chief Executive Officer | $1,215,190 |
| Daniel Virnich | Chief Executive Officer | $808,129 |
| Mihir Shah | Chief Financial Officer | $801,743 |
| Yale Podnos | Chief Medical Officer | $591,284 |
Board service
Starling Oncology board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $75,000 | $240,000 | — | $0 | $315,000 |
| FY2024 | $75,000 | $6,820 | — | $0 | $81,820 |
| FY2023 | $39,167 | $86,584 | — | $0 | $125,751 |
| FY2021 | — | — | — | — | — |
Each year as the company reported it in Starling Oncology's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Starling Oncology pays directors a $75,000 cash retainer and $125,000 in RSUs. As stated in Starling Oncology's FY2025 proxy.
Committees
Compliance Committee
The full Starling Oncology compensation record
free company briefThis page is one person within Starling Oncology's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Starling Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.